PDCD1 and neoplasm: Although programmed cell death protein-1 (PD-1) and PD-L1 inhibitors both target immune checkpoints, their mechanisms of anti-tumor activity are not entirely congruent, and the variability in their efficacy in advanced LCNEC remains poorly understood (34, 35).